Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 07 Jun 2022
U.S. probes how pharmacies set drug prices as costs rise
7 June 2022 - The U.S. Federal Trade Commission has opened a probe into how big pharmacy benefit managers like ...
Posted by Michael Wonder on 07 Jun 2022
AARP continues fight for lower prescription drug prices
7 June 2022 - Older Americans shouldn’t have to choose between their medication and rent or groceries. ...
Posted by Michael Wonder on 07 Jun 2022
Response to engagement on proposals for the Innovative Medicines Fund
7 June 2022 - NHS England and NICE asked for comments on our proposals for the Innovative Medicines Fund. ...
Posted by Michael Wonder on 07 Jun 2022
Patients to have earlier access to cutting edge treatments on NHS
7 June 2022 - The most promising medicines will be fast-tracked to NHS patients through Innovative Medicines Fund ...
Posted by Michael Wonder on 07 Jun 2022
Sifi announces EMA validation of its marketing authorisation application for Akantior for the treatment of acanthamoeba keratitis
7 June 2022 - Sifi has launched an early access program across European countries in June 2022. ...
Posted by Michael Wonder on 07 Jun 2022
The online Pharmaceutical Schedule gets a refresh
7 June 2022 - PHARMAC's online Pharmaceutical Schedule has had a refresh with new features to improve the user experience. ...
Posted by Michael Wonder on 06 Jun 2022
COVID mRNA vaccines can be quickly updated for new variants. So, where's my Omicron booster?
6 June 2022 - Since Omicron was declared a variant of concern at the end of November, it quickly swept ...
Posted by Michael Wonder on 06 Jun 2022
BioCryst announces Health Canada has authorised Orladeyo (berotralstat), the only oral treatment for the prevention of hereditary angioedema attacks
6 June 2022 - BioCryst Pharmaceuticals today announced that Health Canada has approved oral, once daily Orladeyo (berotralstat) for the ...
Posted by Michael Wonder on 06 Jun 2022
Medigen applies for Australian vaccine approval
7 June 2022 - Medigen Vaccine Biologics has applied to the Australian medicines regulator for provisional approval of its COVID-19 ...
Posted by Michael Wonder on 06 Jun 2022
Novavax faces high stakes FDA review this week that will decide the fate of its COVID vaccine in the U.S.
6 June 2022 - If they endorse the vaccine, the FDA will almost certainly authorise the shot for adults in the ...
Posted by Michael Wonder on 06 Jun 2022
Bristol Myers Squibb withdraws supplemental biologics license application for Reblozyl (luspatercept-aamt) for non-transfusion dependent beta thalassaemia
3 June 2022 - Bristol Myers Squibb today announced that the company has withdrawn a supplemental biologics license application for ...
Posted by Michael Wonder on 06 Jun 2022
GBT’s inclacumab and GBT601 receive U.S. FDA orphan drug and rare paediatric disease designations for the treatment of sickle cell disease
6 June 2022 - Inclacumab is a novel P selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive ...
Posted by Michael Wonder on 06 Jun 2022
FDA approves Riabni (rituximab-arrx), a biosimilar to Rituxan (rituximab), for adults with moderate to severe rheumatoid arthritis
6 June 2022 - Now approved to treat all available Rituxan Indications. ...
Posted by Michael Wonder on 06 Jun 2022
GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older
6 June 2022 - Priorix becomes an additional source of measles, mumps and rubella vaccine for US patients ...
Posted by Michael Wonder on 05 Jun 2022
Values, principles, strategies, and frameworks underlying patient and public involvement in health technology assessment and guideline development: a scoping review
3 June 2022 - The importance of patient and public involvement is recognised by agencies involved in health technology assessment and ...